Division of Endocrine, Metabolism and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia.
Front Endocrinol (Lausanne). 2021 Dec 20;12:796194. doi: 10.3389/fendo.2021.796194. eCollection 2021.
Hyperthyroidism is related to vascular atherosclerosis. Propylthiouracil (PTU) and methimazole, other than their antithyroid effects, may have different mechanisms in preventing atherogenesis in Graves' disease.
This study aimed to investigate the effect of antithyroid drugs on markers of vascular atherosclerosis in Graves' hyperthyroidism.
This study was a single-blind, randomized clinical trial conducted on 36 patients with Graves' disease in Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, from June 2019 until July 2020. Graves' disease was diagnosed from clinical manifestation of hyperthyroidism with diffuse goiter and then confirmed by thyroid stimulation hormone (TSH), free T4 (fT4), and TSH-receptor antibody (TRAb) measurements. Participants were randomly assigned to either a PTU or a methimazole treatment group and followed up for 3 months. Markers of vascular atherosclerosis were represented by adhesion molecules [intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin], carotid artery stiffness [pulse wave velocity (PWV)], and thickness [carotid intima media thickness (cIMT)].
By the end of the study, 24 participants reached euthyroid condition (13 from the PTU group and 11 from the methimazole group). After 3 months of follow-up, in the PTU group, we noticed an improvement of ICAM-1 [pretreatment: 204.1 (61.3) vs. posttreatment: 141.6 (58.4) ng/ml; p = 0.001], VCAM-1 [837 (707-977) vs. 510 (402-630) ng/ml; p < 0.001] and E-selectin [32.1 (24.1-42.7) vs. 28.2 (21.6-36.8) ng/ml; p = 0.045] in the PTU group. In the methimazole group, only VCAM-1 improvement [725 (565-904) vs. 472 (367-590); p = 0.001] was observed. Meanwhile, we found no significant changes in PWV or cIMT in either group.
Antithyroid treatment in Graves' disease leads to improvement in adhesion molecules, with a lesser effect on methimazole, whereas there were no significant changes in PWV or cIMT. PTU may have a better mechanism compared with methimazole in terms of improving adhesion molecules.
甲状腺功能亢进与血管动脉粥样硬化有关。丙硫氧嘧啶(PTU)和甲巯咪唑除了具有抗甲状腺作用外,在预防格雷夫斯病的动脉粥样硬化形成方面可能具有不同的机制。
本研究旨在探讨抗甲状腺药物对格雷夫斯病甲状腺功能亢进患者血管动脉粥样硬化标志物的影响。
这是一项在印度尼西亚雅加达 Cipto Mangunkusumo 综合医院进行的单盲、随机临床试验,纳入了 2019 年 6 月至 2020 年 7 月期间的 36 例格雷夫斯病患者。从甲状腺功能亢进的临床表现(弥漫性甲状腺肿)诊断出格雷夫斯病,然后通过促甲状腺激素(TSH)、游离 T4(fT4)和 TSH 受体抗体(TRAb)测量来确认。参与者被随机分配到丙硫氧嘧啶或甲巯咪唑治疗组,并随访 3 个月。血管动脉粥样硬化的标志物由黏附分子[细胞间黏附分子-1(ICAM-1)、血管细胞黏附分子-1(VCAM-1)和 E-选择素]、颈动脉僵硬度[脉搏波速度(PWV)]和厚度[颈动脉内膜中层厚度(cIMT)]来表示。
研究结束时,24 名参与者达到甲状腺功能正常状态(PTU 组 13 名,甲巯咪唑组 11 名)。经过 3 个月的随访,PTU 组发现 ICAM-1[治疗前:204.1(61.3)vs. 治疗后:141.6(58.4)ng/ml;p=0.001]、VCAM-1[837(707-977)vs. 510(402-630)ng/ml;p<0.001]和 E-选择素[32.1(24.1-42.7)vs. 28.2(21.6-36.8)ng/ml;p=0.045]水平改善。而在甲巯咪唑组,仅观察到 VCAM-1 改善[725(565-904)vs. 472(367-590);p=0.001]。同时,我们发现两组的 PWV 或 cIMT 均无显著变化。
抗甲状腺治疗格雷夫斯病可改善黏附分子,甲巯咪唑的作用较小,而 PWV 或 cIMT 无明显变化。PTU 在改善黏附分子方面可能比甲巯咪唑具有更好的机制。